methyl 3-(o-tolyl)isonicotinate | 355008-55-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methyl 3-(o-tolyl)isonicotinate
• 英文别名: 3-(2-methylphenyl) isonicotinic acid, methyl ester；3-(2-Methylphenyl)-4-pyridinecarboxylic acid methyl ester；methyl 3-(2-methylphenyl)pyridine-4-carboxylate
• CAS: 355008-55-8
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: YCEXHYXJCGNDGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  methyl 3-(o-tolyl)isonicotinate 在 盐酸 、 1-氯乙基氯甲酸酯 、 sodium cyanoborohydride 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 生成 methyl (2S)-2-[[1-[benzyl(1,3-thiazol-5-ylmethyl)carbamoyl]-5-(2-methylphenyl)-3,6-dihydro-2H-pyridine-4-carbonyl]amino]-4-methylsulfanylbutanoate
  参考文献：
  名称：

  Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives

  摘要：

  Inhibitors of farnesyltransferase are effective against a variety of tumors in mouse models of cancer. Clinical trials to evaluate these agents in humans are ongoing. In our effort to develop new farnesyltransferase inhibitors, we have discovered a series of aryl tetrahydropyridines that incorporate substituted glycine, phenylalanine and histidine residues. The design, synthesis, SAR and biological properties of these compounds will be discussed. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00095-7
• 作为产物：
  描述：

  3-氨基-4-吡啶羧酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 氯化亚砜 、 cesium fluoride 、 potassium iodide 、 sodium nitrite 作用下， 生成 methyl 3-(o-tolyl)isonicotinate
  参考文献：
  名称：

  Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives

  摘要：

  Inhibitors of farnesyltransferase are effective against a variety of tumors in mouse models of cancer. Clinical trials to evaluate these agents in humans are ongoing. In our effort to develop new farnesyltransferase inhibitors, we have discovered a series of aryl tetrahydropyridines that incorporate substituted glycine, phenylalanine and histidine residues. The design, synthesis, SAR and biological properties of these compounds will be discussed. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00095-7

文献信息

• INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
  申请人：Praxis Biotech LLC

  公开号：US20190185451A1

  公开（公告）日：2019-06-20

  Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

  描述了用于调节成纤维细胞活化蛋白（FAP）的化合物和组合物。这些化合物和组合物可能被用作治疗疾病的治疗剂，包括高增殖性疾病。
• Inhibitors of protein isoprenyl transferases
  申请人：Abbott Laboratories

  公开号：US06277871B1

  公开（公告）日：2001-08-21

  The present invention relates to novel compounds of Formula I which are useful in inhibiting protein isoprenyl transferases and the farnesylation or geranylgeranylation of the oncogene protein Ras and other related small g-proteins, and compositions containing such compounds and methods of using such compounds.

  本发明涉及一种新型化合物，其化学式为I，可用于抑制蛋白异戊二烯基转移酶以及致癌基因蛋白Ras和其他相关小G蛋白的法尼醇化或杜鲁醇化，以及含有这种化合物的组合物和使用这种化合物的方法。
• [EN] INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN<br/>[FR] INHIBITEURS DE LA PROTÉINE D'ACTIVATION DES FIBROBLASTES
  申请人：PRAXIS BIOTECH LLC

  公开号：WO2019118932A1

  公开（公告）日：2019-06-20

  Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
• Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives
  作者：Stephen L. Gwaltney、Stephen J. O'Connor、Lissa T.J. Nelson、Gerard M. Sullivan、Hovis Imade、Weibo Wang、Lisa Hasvold、Qun Li、Jerome Cohen、Wen-Zhen Gu、Stephen K. Tahir、Joy Bauch、Kennan Marsh、Shi-Chung Ng、David J. Frost、Haiying Zhang、Steve Muchmore、Clarissa G. Jakob、Vincent Stoll、Charles Hutchins、Saul H. Rosenberg、Hing L. Sham

  DOI：10.1016/s0960-894x(03)00095-7

  日期：2003.4

  Inhibitors of farnesyltransferase are effective against a variety of tumors in mouse models of cancer. Clinical trials to evaluate these agents in humans are ongoing. In our effort to develop new farnesyltransferase inhibitors, we have discovered a series of aryl tetrahydropyridines that incorporate substituted glycine, phenylalanine and histidine residues. The design, synthesis, SAR and biological properties of these compounds will be discussed. (C) 2003 Elsevier Science Ltd. All rights reserved.